About ATP-sensitive inward rectifier potassium channel 15
ATP-sensitive inward rectifier potassium channel 15 (KCNJ15) is a protein
from Homo sapiens identified by UniProt accession
Q99712, 375 residues long.
MolForge cross-references it against 0 known binders and
128 disease associations.
Target properties
| Protein name | ATP-sensitive inward rectifier potassium channel 15 |
| UniProt accession | Q99712 |
| Gene | KCNJ15 |
| Organism | Homo sapiens |
| Length | 375 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (128)
Diseases linked to this target (Open Targets).
- body height · score 0.49
- lean body mass · score 0.47
- appendicular lean mass · score 0.43
- body weight · score 0.43
- fat body mass · score 0.38
- BMI-adjusted hip circumference · score 0.37
- Immature Reticulocyte Fraction Measurement · score 0.36
- reticulocyte measurement · score 0.35
- reticulocyte count · score 0.35
- BMI-adjusted waist-hip ratio · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99712-F1 | alphafold | PREDICTED | 85.31 | — |
Amino-acid sequence (375 residues)
MDAIHIGMSS TPLVKHTAGA GLKANRPRVM SKSGHSNVRI DKVDGIYLLY LQDLWTTVID MKWRYKLTLF AATFVMTWFL FGVIYYAIAF IHGDLEPGEP ISNHTPCIMK VDSLTGAFLF SLESQTTIGY GVRSITEECP HAIFLLVAQL VITTLIEIFI TGTFLAKIAR PKKRAETIKF SHCAVITKQN GKLCLVIQVA NMRKSLLIQC QLSGKLLQTH VTKEGERILL NQATVKFHVD SSSESPFLIL PMTFYHVLDE TSPLRDLTPQ NLKEKEFELV VLLNATVEST SAVCQSRTSY IPEEIYWGFE FVPVVSLSKN GKYVADFSQF EQIRKSPDCT FYCADSEKQQ LEEKYRQEDQ RERELRTLLL QQSNV
Explore ATP-sensitive inward rectifier potassium channel 15 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets